Clinical Studies Sponsored by Fate Therapeutics

Clinical Studies Sponsored by Fate Therapeutics

Clinical Studies Sponsored by University of Wyoming

Clinical Studies Sponsored by University of Central Florida

Clinical Studies Sponsored by Georgetown University

List of companies in Caravela Capital's investment portfolio

CEOs of designer companies

Clinical Studies where

Trial Sponsor

is

	Name	Description	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
	‌ FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors		NCT06241456		January 5, 2024	May 1, 2044	Interventional
	‌ FT819 in Moderate to Severe Active Systemic Lupus Erythematosus		NCT06308978	Systemic lupus erythematosus	February 24, 2024	September 30, 2042	Interventional
	‌ Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies		NCT00890500		2011	2013	Interventional
	‌ FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors		NCT05395052	Colorectal cancer Pancreatic cancer Ovarian cancer Head and neck cancer ‌ Breast Cancer	May 31, 2022	August 11, 2023	Interventional
	‌ Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy		NCT04106167	Cervical cancer Lymphoma Colorectal cancer Hepatocellular carcinoma Renal cell carcinoma Melanoma Head and neck cancer Microsatellite instability ‌ Squamous cell carcinoma	June 11, 2019	August 11, 2023	Observational
	‌ FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors		NCT04551885		September 7, 2020	August 11, 2023	Interventional
	‌ Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy		NCT04093622		October 4, 2019	April 9, 2020	Observational
	‌ FT819 in Subjects With B-cell Malignancies		NCT04629729		July 26, 2021	September 30, 2039	Interventional
	‌ FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors		NCT03319459	Colorectal cancer Hepatocellular carcinoma Pancreatic cancer Renal cell carcinoma Melanoma	January 18, 2018	December 15, 2020	Interventional
	‌ A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies		NCT02354417		2014	2017	Interventional
	‌ A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders		NCT02354443		2015	2017	Interventional
	‌ The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies		NCT01627314		2012	2017	Interventional
	‌ FT516 in Subjects With Advanced Hematologic Malignancies		NCT04023071	B-cell lymphoma	October 4, 2019	October 23, 2023	Interventional
	‌ FT576 in Subjects With Multiple Myeloma		NCT05182073	Multiple myeloma	November 24, 2021	2040	Interventional
	‌ FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma		NCT05934097	‌ Follicular lymphoma Mantle cell lymphoma	2022	2039	Interventional
	‌ Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit		NCT01527838		2012	2013	Interventional

16 results

0 selected

16 results

0 selected